Biocaxis > Products > Nucleoside |
|
|||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||
5-Methylcyclocytidine hydrochloride
Catalog NO.: NS-007
| CAS NO.: 51391-96-9 |
Brand: BIOCAXIS
Category
Nucleosides & Nucleotides, nucleobase
Synonyms:
O-2,3'-Anhydro-5-methylcytidine hydrochloride;
6H-Furo[2',3':4,5]oxazolo[3,2-a]pyrimidine-2-methanol,
2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-7-methyl-, monohydrochloride,
[2R-(2α,3β,3aβ,9aβ)]-;
(2R,3R,3aS,9aR)-2-(Hydroxymethyl)-6-imino-7-methyl-3,3a,6,9a-tetrahydro-2H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-3-ol
Hydrochloride; CMC.HCl
Molecular Formula
C10H14ClN3O4
Molecular Weight
275.69
General description
5-Methylcyclocytidine hydrochlorine,
a nucleoside analogue of cytidine, exhibits profound biomedical implications in
combating specific ailments. Its inherent capability to impede nucleotide
synthesis and viral replication positions it as a prospective anticancer and
antiviral agent. However, elucidating its complete therapeutic prowess
necessitates further comprehensive investigation, thus underscoring the
importance of conducting extensive scientific research.
5-Methylcyclocytidine hydrochloride is a purine nucleoside
analog. Purine nucleoside analogs have broad antitumor activity targeting
indolent lymphoid malignancies. Anticancer mechanisms in this process rely on
inhibition of DNA synthesis, induction of apoptosis, etc.